News and reporting on cancer immunotherapy.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.
The certification enables the company to offer its flow cytometry-based myeloid-derived suppressor cell assay for cancer patients.
Data for hundreds of breast tumors suggested specific signatures were more closely linked to tumor-infiltrating lymphocyte activity than was mutational load.
The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.